1. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A.Global cancer statistics 2018: GLOBOCAN estimates of incidence andmortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin.2018;68(6):394-424.
2. Akinyemiju T, Abera S, Ahmed M, et al. The burden of primary livercancer and underlying etiologies from 1990 to 2015 at the global,regional, and national level: results from the global burden of diseasestudy 2015. JAMA Oncol. 2017;3(12):1683-1691.
3. Toh MR, Wong EYT, Wong SH, et al. Global epidemiology and geneticsof hepatocellular carcinoma. Gastroenterol. 2023;164(5):766-782.
4. Llovet JM, Castet F, Heikenwalder M, et al. Immunotherapies forhepatocellular carcinoma. Nat Rev Clin Oncol. 2022;19(3):151-172.
5. Sakamoto M, Mori T, Masugi Y, Effendi K, Rie I, Du W. Candidatemolecular markers for histological diagnosis of early hepatocellularcarcinoma. Intervirol. 2008;51(Suppl 1):42-45.
6. Pinero F, Dirchwolf M, Pessoa MG. Biomarkers in hepatocellularcarcinoma: diagnosis, prognosis and treatment response assessment.Cells. 2020;9(6):1370.
7. Wang H, Pan K, Zhang HK, et al. Increased polycomb-group oncogeneBmi-1 expression correlates with poor prognosis in hepatocellularcarcinoma. J Cancer Res Clin Oncol. 2008;134(5):535-541.
8. Sakamoto K, Ogawa K, Tohyama T, et al. Serosal invasion is a strongprognostic factor for hepatocellular carcinoma after hepatectomy.Hepatol Res. 2019;49(4):419-431.
9. Alawyia B, Constantinou C. Hepatocellular carcinoma: a narrativereview on current knowledge and future prospects. Curr Treat OptionsOncol. 2023;24(7):711-724.
10. Ding J, Wen Z. Survival improvement and prognosis for hepatocellularcarcinoma: analysis of the SEER database. BMC Cancer. 2021;21(1):1157.
11. Sarveazad A, Agah S, Babahajian A, Amini N, Bahardoust M.Predictors of 5 year survival rate in hepatocellular carcinoma patients.J Res Med Sci. 2019;24:86.
12. Luk JM, Lam CT, Siu AF, et al. Proteomic profiling of hepatocellularcarcinoma in Chinese cohort reveals heat-shock proteins (Hsp27,Hsp70, GRP78) up-regulation and their associated prognostic values.Proteomics. 2006;6(3):1049-1057.
13. Gehrmann M, Cervello M, Montalto G, et al. Heat shock protein 70serum levels differ significantly in patients with chronic hepatitis, livercirrhosis, and hepatocellular carcinoma. Front Immunol. 2014;5:307.
14. Diehl JA, Yang W, Rimerman RA, Xiao H, Emili A. Hsc70 regulatesaccumulation of cyclin D1 and cyclin D1-dependent protein kinase.Mol Cell Biol. 2003;23(5):1764-1774.
15. Calderwood SK, Khaleque MA, Sawyer DB, Ciocca D. Heat shockproteins in cancer: chaperones of tumorigenesis. Trends Biochem Sci.2006;31(3):164-172.
16. Joo M, Chi JG, Lee H. Expressions of HSP70 and HSP27 inhepatocellular carcinoma. J Korean Med Sci. 2005;20(5):829-834.
17. Lim SO, Park SG, Yoo JH, et al. Expression of heat shock proteins(HSP27, HSP60, HSP70, HSP90, GRP78, GRP94) in hepatitis B virus-related hepatocellular carcinomas and dysplastic nodules. World JGastroenterol. 2005;11(14):2072-2079.
18. Kang GH, Lee BS, Lee ES, Kim SH, Lee HY, Kang DY. Prognosticsignificance of p53, mTOR, c-Met, IGF-1R, and HSP70 overexpressionafter the resection of hepatocellular carcinoma. Gut Liver. 2014;8(1):79-87.
19. Dai W, Zong WX. Glutamine synthetase: a tumor suppressor inhepatocellular carcinoma? J Mol Cell Biol. 2023;15(1):mjad007.
20. Dai W, Shen J, Yan J, et al. Glutamine synthetase limits beta-catenin-mutated liver cancer growth by maintaining nitrogen homeostasis andsuppressing mTORC1. J Clin Invest. 2022;132(24):e161408.
21. Uthamalingam P, Das A, Behra A, Kalra N, Chawla Y. Diagnosticvalue of glypican3, heat shock protein 70 and glutamine synthetase inhepatocellular carcinoma arising in cirrhotic and non-cirrhotic livers. JClin Exp Hepatol. 2018;8(2):173-180.
22. Morita M, Nishida N, Sakai K, et al. Immunological microenvironmentpredicts the survival of the patients with hepatocellular carcinomatreated with anti-PD-1 antibody. Liver Cancer. 2021;10(4):380-393.
23. Fu J, Li M, Wu DC, Liu LL, Chen SL, Yun JP. Increased expression ofCAP2 indicates poor prognosis in hepatocellular carcinoma. TranslatOncol. 2015;8(5):400-406.
24. Mohammed MA, Moustafa Omar N, Mohammed SA, Galal Deiab A.Identification of cyclase-associated protein-2 as a novel biomarker forearly-stage hepatocellular carcinoma. J Clin Gastroenterol Hepatol.2017;1(3):26.
25. Steele JC, Torr EE, Noakes KL, et al. The polycomb group proteins,BMI-1 and EZH2, are tumour-associated antigens. Br J Cancer.2006;95(9):1202-1211.
26. Liu Y, Yang Q. The roles of EZH2 in cancer and its inhibitors. MedOncol. 2023;40(6):167.
27. Li X, Yang Z, Song W, et al. Overexpression of Bmi-1 contributes to theinvasion and metastasis of hepatocellular carcinoma by increasing theexpression of matrix metalloproteinase (MMP)-2, MMP-9 and vascularendothelial growth factor via the PTEN/PI3K/Akt pathway. Int J Oncol.2013;43(3):793-802.
28. Lee RM, Russell MC. Is screening for hepatocellular carcinomaeffective? Adv Surg. 2023;57(1):73-86.
29. Zhang L, Li HT, Shereda R, et al. DNMT and EZH2 inhibitors synergizeto activate therapeutic targets in hepatocellular carcinoma. Cancer Lett.2022;548:215899.
30. Fu WM, Zhu X, Wang WM, et al. Hotair mediates hepatocarcinogenesisthrough suppressing miRNA-218 expression and activating P14 andP16 signaling. J Hepatol. 2015;63(4):886-895.